Effectiveness and safety of biosimilars in pediatric inflammatory bowel diseases: an observational longitudinal study on the French National Health Data System
Authors:
- 23 January 2025
- journal article
- research article
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 21 (1) , 62-72
Abstract
Background Data on biosimilar use in pediatric inflammatory bowel diseases (IBD) are scarce compared to the status of studies in adults, resulting in limitations in its treatment. We compared effectiveness and safety of biosimilars versus originators in this population. Methods We used data from the French National Health Data System to identify children (less than 18 years old at treatment initiation) initiating treatment with a biosimilar or the originator infliximab or adalimumab for Crohn’s disease (CD) or ulcerative colitis (UC), from first biosimilar launch (January 2015 and October 2018, respectively) to 31 December 2022. Patients’ follow-up went until 30 June 2023. We compared the risks of treatment failure and overnight hospitalization in biosimilar versus originator new users using inverse harzard ratio (HR) of probability of treatment weighted Cox regressions (IPTW). Results We included 5870 patients (infliximab: n = 3491; adalimumab: n = 2379) in the study. Biosimilars represented, respectively, 76.0% (n = 2652) and 29.0% (n = 691) of infliximab and adalimumab initiations. CD represented 70.9% (n = 2476) and 69.0% (n = 1642) of infliximab and adalimumab initiations. Biosimilar use was not associated with increased risks of treatment failure [IPTW HR (95% confidence interval, CI): infliximab 0.92 (0.78–1.09) in CD, 0.98 (0.76–1.27) in UC; adalimumab 0.98 (0.85–1.14) in CD, 1.01 (0.82–1.24) in UC]. Occurrence of all-cause hospitalization was not different between exposure groups [IPTW HR (95% CI): infliximab 0.96 (0.78–1.18); adalimumab 1.03 (0.80–1.33)]. No difference in occurrence of serious infections, mainly gastro-intestinal or dermatological, was found. Conclusion We provide reassuring results on the use, effectiveness and safety of biosimilars in a large unselected pediatric population suffering from IBD.Keywords
This publication has 43 references indexed in Scilit:
- COVID-19 Hospitalization in Solid Organ Transplant Recipients on Immunosuppressive TherapyJAMA Network Open, 2023
- Severe Hypersensitivity Reactions at Biosimilar versus Originator Rituximab Treatment Initiation, Switch and Over Time: A Cohort Study on the French National Health Data SystemBioDrugs, 2023
- Association Between Doses of Levonorgestrel Intrauterine Systems and Subsequent Use of Psychotropic Drugs in FranceJAMA, 2023
- Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With PsoriasisJAMA Dermatology, 2022
- Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance DatabaseJAMA Dermatology, 2022
- Association Between Biologics Use and Risk of Serious Infection in Patients With PsoriasisJAMA Dermatology, 2021
- Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and EffectivenessAdvances in Therapy, 2021
- Inflammatory Bowel Disease in Children and AdolescentsJAMA Pediatrics, 2015
- The Active Comparator, New User Study Design in Pharmacoepidemiology: Historical Foundations and Contemporary ApplicationCurrent Epidemiology Reports, 2015
- Natural history of Crohnʼs diseaseInflammatory Bowel Diseases, 2010